Good MorningEquity markets continued to decline last week after inflation data pointed to a high likelihood of additional FOMC interest rates. The steady pace of CPI combined with hotter-than-expected PPI and rising oil prices suggests that inflation could accelerate and drive the FOMC to hike rates not 1 more time but 2 or more. In this scenario, there will be multiple bank failures and a curb on consumer demand unlike any in more than half a century.
The S&P 500 shed about a half percent, moving to a 1-month low for the week. There are no significant targets for solid support above the 150-day EMA, so a larger decline is expected. A move down to that level would be worth another 4.5% for the broad market and open the door to an even deeper decline. This week, the FOMC minutes will give additional clues to the FOMCs next move and could move the market. Featured: Trump goes "all-in" on Grand Canyon energy breakthrough (Ad) 
|
Energy | |
Exxon Mobil Corp. (NYSE: XOM) has been struggling below resistance near $119 as it forms a follow-on base after undercutting previous structure lows.
The stock has been quietly rallying in recent weeks, notching small weekly gains in above-average turnover. Its one-month return is 5.19%, which is... Read the Full Story |
|
From Our Partners | | Rumors are circulating that Elon Musk is preparing to acquire three publicly traded companies.
Dr. Mark Skousen, who met Musk in person and called the SpaceX listing months early, says he has identified all three targets in what he calls Elon's $2.1 Trillion Hit List.
See the three companies before the rumors become headlines. | | Get the details on all three companies now |
|
Technology | |
With earnings season well underway, investors are watching pretty much every industry closely. Banks, for example, need to show they can continue benefiting from the rising rates cycle, while tech needs to show it's finally returning to consistent growth. Both industries have seen just how exposed... Read the Full Story |
|
Healthcare | |
There’s a reason why many investors own one or more pharmaceutical stocks. This is a $1.2 trillion industry that is essential to the quality of life for many people. And every year, companies in this sector are getting closer to real breakthroughs in areas like diabetes, cancer, even Alzheim... Read the Full Story |
|
From Our Partners | | Palantir, Micron and SanDisk show how fast a stock can become the trade everyone suddenly wants. That's often when investors make their costliest mistake: arriving after the easy part of the move is gone.
A new premium eBook flags 7 stocks that may be worth knowing about before the broader crowd catches on. You don't need to buy any of them - just knowing what's quietly gaining attention can be useful. | | See the 7 stocks on the watchlist while it's still free |
|
Industrials | |
Plug Power's (NASDAQ: PLUG) share price fell more than 15% following the Q2 release and no wonder. The timetables for the full commissioning of its flagship green hydrogen-producing plants have been pushed out by at least 2 quarters. That and the mounting losses have raised questions and concerns ... Read the Full Story |
|
Technology | |
The technology sector, which has been the top-performing sector this year, has seen a minor decline this week. The Invesco QQQ Trust (NASDAQ: QQQ) has retreated by 1.38% this week. Although the ETF's value is still comfortably above its steadily increasing 200-day SMA, it dipped below its 20-day S... Read the Full Story |
|
From Our Partners | | SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in could be a costly mistake. He calls it among the most overhyped, overvalued large-cap offerings ever pushed onto everyday investors.
Tilson believes a rare economic event is approaching - one with serious consequences for your portfolio this summer. He has prepared a free analysis outlining what he sees and the specific steps he recommends taking now. | | Read Tilson's free analysis and find out what to do with your money |
|
Industrials | |
FREYR Battery (NYSE: FREY) is another in a long line of green-energy and next-gen technology companies working to make a difference. The difference with this company is that its technology is proven, it has binding orders worth billions, and testing the first products is already underway.
Based o... Read the Full Story |
|
Finance | |
An analyst from Morgan Stanley (NYSE: MS) recently stated that the AI bubble was in its late inning. The analyst’s thesis is that the performance of Nvidia Corporation (NASDAQ: NVDA) stock is a proxy for the AI sector.
But the thing about a bubble that bursts is there are ripples that exte... Read the Full Story |
|
Markets | |
Despite a summer slowdown in the US job market, it remains resilient against recession predictions and higher interest rates. July added 187,000 jobs, slightly below expectations, yet the unemployment rate fell to 3.5%. The Federal Reserve's interest rate hikes haven't triggered a downturn, and mo... Read the Full Story |
|
Consumer Discretionary | |
Inflation trends in the United States have been improving in the past few months, all thanks to the efforts and initiatives taken by the FED. Rising interest rates may concern some investors, especially when the effects of hikes take a toll on some chosen sectors, namely cyclical consumer spaces. ... Read the Full Story |
|
Consumer Staples | |
Global financial crises. A pandemic. Recession. Countless geopolitical conflicts.
A lot has happened over the last 10 years.
The U.S. stock market has been rattled by a range of events and yet sits within 7% of an all-time high. Along the way, however, many publicly traded companies have gone b... Read the Full Story |
|
Monday's Early Bird Stock Of The Day Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts. | | View Today's Stock Pick |
|
